Comparison of Day 14 Serum Progesterone Level Based on Pregnancy Outcome in Patients Undergoing Intracytoplasmic Sperm Injection Cycles


1 IVF Subspecialist, Infertility Research Center, Mehr Medical Institute, Rasht, Iran

2 Master of Developmental Biology, Infertility Research Center, Mehr Medical Institute, Rasht, Iran

3 General Practitioner, Infertility Research Center, Mehr Medical Institute, Rasht, Iran

4 Gynecologist, Infertility Research Center, Mehr Medical Institute, Rasht, Iran

5 Professor of Embriology, Infertility Research Center, Mehr Medical Institute, Rasht, Iran


Background & Aims: Serum progesterone level (as early as 4 weeks gestation) reflects the relation between embryo and corpus luteum. The purpose of the present study was to compare serum progesterone level on day 14 after embryo transfer among 3 groups of patients undergoing intracytoplasmic sperm injection (ICSI) cycles; normal pregnancy (viable intrauterine pregnancy), abnormal pregnancy (miscarriage, ectopic, and biochemical pregnancy), or nonpregnant. Methods: In the present study, 103 patients undergoing ICSI, were retrospectively analyzed. They were divided into 3 groups according to pregnancy outcome; normal pregnancy, abnormal pregnancy, and nonpregnant. Baseline and stimulation characteristics and day 14 progesterone level of patients were compared among groups. Results: Day 14 serum progesterone levels were significantly different among groups; 54.3 ng/ml in normal pregnancy, 39.8 ng/ml in abnormal pregnancy, and 26.2 ng/ml in nonpregnant groups (P < 0.001). No significant differences were observed among the groups in terms of age (P = 0.081), BMI (P = 0.247), baseline follicle-stimulating hormone (FSH) (P = 0.133), and baseline anti-Mullerian hormone (AMH) (P = 0.576), male factor infertility (P = 0.790), total number of retrieved oocyte (P = 0.891), metaphase II oocytes (P = 0.918), and estradiol level on the day of human chorionic gonadotropin (HCG) or human menopausal gonadotropin (HMG) administration (P = 0.838). We determined the 39.5 ng/ml progesterone concentration as the cut-off point with 62% sensitivity and 69% specificity. Conclusion: Despite using the same dose of progesterone supplements, day 14 serum progesterone level was significantly higher in women who achieved normal pregnancy after ICSI compared with others.


  1. Khan-Dawood FS, Goldsmith LT, Weiss G, Dawood MY. Human corpus luteum secretion of relaxin, oxytocin, and progesterone. J Clin Endocrinol Metab 1989; 68(3): 627-31.
  2. Norman RJ, Buck RH, Kemp MA, Joubert SM. Impaired corpus luteum function in ectopic pregnancy cannot be explained by altered human chorionic gonadotropin. J Clin Endocrinol Metab 1988; 66(6): 1166-70.
  3. Fernandez H, Gervaise A. Ectopic pregnancies after infertility treatment: modern diagnosis and therapeutic strategy. Hum Reprod Update 2004; 10(6): 503-13.
  4. Murray H, Baakdah H, Bardell T, Tulandi T. Diagnosis and treatment of ectopic pregnancy. CMAJ 2005; 173(8): 905-12.
  5. Elson J, Salim R, Tailor A, Banerjee S, Zosmer N, Jurkovic D. Prediction of early pregnancy viability in the absence of an ultrasonically detectable embryo. Ultrasound Obstet Gynecol 2003; 21(1): 57-61.
  6. Hanita O, Hanisah AH. Potential use of single measurement of serum progesterone in detecting early pregnancy failure. Malays J Pathol 2012; 34(1): 41-6.
  7. Ioannidis G, Sacks G, Reddy N, Seyani L, Margara R, Lavery S, et al. Day 14 maternal serum progesterone levels predict pregnancy outcome in IVF/ICSI treatment cycles: a prospective study. Hum Reprod 2005; 20(3): 741-6.
  8. Sonntag B, Loebbecke KC, Nofer JR, Kiesel L, Greb RR. Serum estradiol and progesterone in the mid-luteal phase predict clinical pregnancy outcome in IVF/ICSI cycles. Gynecol Endocrinol 2013; 29(7): 700-3.
  9. Kim JH, Shin MS, Yi G, Jee BC, Lee JR, Suh CS, et al. Serum biomarkers for predicting pregnancy outcome in women undergoing IVF: human chorionic gonadotropin, progesterone, and inhibin A level at 11 days post-ET. Clin Exp Reprod Med 2012; 39(1): 28-32.
  10. Macklon NS, Fauser BC. Impact of ovarian hyperstimulation on the luteal phase. J Reprod Fertil Suppl 2000; 55: 101-8.
  11. Beckers NG, Laven JS, Eijkemans MJ, Fauser BC. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization. Hum Reprod 2000; 15(1): 43-9.
  12. Tavaniotou A, Albano C, Smitz J, Devroey P. Impact of ovarian stimulation on corpus luteum function and embryonic implantation. J Reprod Immunol 2002; 55(1-2): 123-30.
  13. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 2002; 17(9): 2287-99.
  14. al-Ramahi M, Perkins S, Claman P. Serum progesterone in predicting pregnancy outcome after assisted reproductive technology. J Assist Reprod Genet 1999; 16(3): 117-20.
  15. Vicdan K, Zeki IA. Luteal phase hormonal profile in prediction of pregnancy outcome after assisted reproduction. Eur J Obstet Gynecol Reprod Biol 2001; 96(1): 98-101.
  16. Katsikis I, Rousso D, Farmakiotis D, Kourtis A, Diamanti-Kandarakis E, Panidis D. Receiver operator characteristics and diagnostic value of progesterone and CA-125 in the prediction of ectopic and abortive intrauterine gestations. Eur J Obstet Gynecol Reprod Biol 2006; 125(2): 226-32.
  17. Buck RH, Joubert SM, Norman RJ. Serum progesterone in the diagnosis of ectopic pregnancy: a valuable diagnostic test? Fertil Steril 1988; 50(5): 752-5.
  18. Peterson CM, Kreger D, Delgado P, Hung TT. Laboratory and clinical comparison of a rapid versus a classic progesterone radioimmunoassay for use in determining abnormal and ectopic pregnancies. Am J Obstet Gynecol 1992; 166(2): 562-6.
  19. Cabar FR, Fettback PB, Pereira PP, Zugaib M. Serum markers in the diagnosis of tubal pregnancy. Clinics (Sao Paulo) 2008; 63(5): 701-8.